NEW KEFLEX STRENGTHS APPROVED

Advancis Pharmaceutical has received approval from the FDA to market its antibiotic Keflex in two new strengths, the company said.

Keflex (cephalexin capsules, USP) will now be available in 333-mg and 750-mg tablets. The latter will be a more convenient way to prescribe a 1500-mg daily dosage -- the most common one issued used by doctors -- than the current 250-mg and 500-mg tablets, the company said. Advancis expects to begin marketing the new strengths in July.

Keflex, a first generation cephalosporin antibiotic, is used in the treatment of the respiratory tract infections, otitis media, skin and skin structure infections, bone infections and genitourinary tract infections.